← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Marpam Pharma, Llc
St. Paul, MN
$5,442,305
Total funding
5
Grants
Funding over time
peak $1.3M · FY2020–25$2M$1.5M$1M$500K$0
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,442,305 · 5
By mechanism
R42$4,481,557 · 2
R41$960,748 · 3
Investigators at Marpam Pharma, Llc
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
Development of a treatment for the durable remission of HIV using autologous human CAR T cells that target B cell follicles$1,018,997
R42 · FY2021 · AI
Development of a treatment for the durable remission of HIV using autologous human CAR T cells that target B cell follicles$1,009,537
R42 · FY2022 · AI
A novel CAR-T cell therapy for the one-time treatment of chronic HIV infection in patients who are not ART suppressed$1,000,449
R42 · FY2024 · AI
A novel CAR-T cell therapy for the one-time treatment of chronic HIV infection in patients who are not ART suppressed$979,050
R42 · FY2025 · AI
Development of a treatment for durable remission of HIV using transposon engineered CAR-T and NK cells$306,500
R41 · FY2023 · AI
Proof of concept studies for in vivo produced CAR-T cells that target B cell follicles as a treatment for HIV$302,248
R41 · FY2024 · AI
A novel CAR-T cell therapy for the one-time treatment of chronic HIV infection in patients who are not ART suppressed$300,000
R42 · FY2022 · AI
Development of a treatment for the durable remission of HIV using autologous human CAR T cells that target B cell follicles$300,000
R41 · FY2020 · AI
Development of a treatment for the durable remission of HIV using autologous human CAR T cells that target B cell follicles$118,524
R42 · FY2023 · AI
A novel CAR-T cell therapy for the one-time treatment of chronic HIV infection in patients who are not ART suppressed$55,000
R42 · FY2023 · AI
Development of a treatment for the durable remission of HIV using autologous human CAR T cells that target B cell follicles$52,000
R41 · FY2021 · AI